01—Abstract
Summary
Summary of the 8-K filed February 11, 2026. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) announced via an 8-K filing on February 11, 2026, that it received a Refusal-to-File letter from the U.S. Food and Drug Administration (FDA) for its investigational seasonal influenza vaccine, mRNA-1010.
This means the FDA will not initiate a review of the Biologics License Application (BLA) for this vaccine candidate at this time. The company furnished a press release dated February 10, 2026, detailing this development, which is included as an exhibit to the filing.
This news represents a significant setback for the mRNA-1010 program and could impact Moderna's influenza vaccine pipeline and competitive positioning in the seasonal flu market. Investors should closely monitor any further communication from Moderna regarding the specific reasons for the FDA's decision and the company's plans for addressing these concerns, including potential resubmission strategies or reallocation of resources.
02—Key points
Key Highlights
- FDA issued a Refusal-to-File letter for Moderna's investigational seasonal influenza vaccine, mRNA-1010.
- The FDA's Center for Biologics Evaluation and Research (CBER) will not initiate a review of the Biologics License Application (BLA) for mRNA-1010.
- The company announced this development via a press release dated February 10, 2026.
- This news is considered a material event, disclosed under Item 8.01 (Other Events) and Item 7.01 (Regulation FD Disclosure) of the 8-K filing.
- The filing includes the press release as Exhibit 99.1.
- This decision represents a delay or potential halt for the mRNA-1010 program.
03—Questions
Frequently Asked Questions
What is a Refusal-to-File letter from the FDA?
A Refusal-to-File letter from the FDA means that the agency has determined that a submitted application (in this case, a Biologics License Application or BLA) does not meet the minimum requirements for them to begin a substantive review. The FDA will not proceed with evaluating the safety and efficacy of the product based on the current submission.
What are the immediate implications of this FDA decision for Moderna?
The immediate implication is that Moderna's mRNA-1010 seasonal influenza vaccine candidate will not be moving forward in the FDA approval process at this time. This is a significant setback for the program and could impact Moderna's revenue projections and market share in the influenza vaccine space.
Will Moderna be able to resubmit the application for mRNA-1010?
The filing does not explicitly state if Moderna can resubmit or what the pathway would be. Typically, a Refusal-to-File letter indicates deficiencies that need to be addressed before a resubmission can be considered. Investors should look for further communication from Moderna regarding the specific reasons for the refusal and their plans to address them.
Does this FDA decision affect other Moderna vaccine programs?
This specific Refusal-to-File letter pertains only to the investigational seasonal influenza vaccine, mRNA-1010. It does not directly impact other vaccine candidates in Moderna's pipeline, such as those for COVID-19 or other diseases, unless the underlying issues are systemic or affect manufacturing processes broadly.
04—Continue